[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]trimethyl-sulfamide | 454219-11-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]trimethyl-sulfamide
• 英文别名: N''methyl-[4-(2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)phenyl]-N,N-dimethylsulfamide；(1R)-1-(3-chlorophenyl)-2-[2-[4-[dimethylsulfamoyl(methyl)amino]phenyl]ethylamino]ethanol
• CAS: 454219-11-5
• 化学式: C₁₉H₂₆ClN₃O₃S
• 分子量: 411.953
• InChiKey: AULBTWGSEOLSAY-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  81.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]trimethyl-sulfamide 生成 [4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]trimethyl-sulfamide, dihydrochloride
  参考文献：
  名称：

  Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof

  摘要：

  公式（I）的磺胺化合物被描述，并且它们被用于治疗依赖于与β-肾上腺素受体相关的信号通路的疾病，例如肥胖症、糖尿病、高血压、胃肠道低动力或高动力以及心血管疾病。

  公开号：

  EP1236723A1
• 作为产物：
  描述：

  4-硝基苯乙胺 在 吡啶 、 氢氧化钾 、 乙醇 、 N,O-bis(trimethylsilyl) acetamide 、 tin(ll) chloride 、 lithium hexamethyldisilazane 作用下， 以 乙醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 2.0h， 生成 [4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenyl]trimethyl-sulfamide
  参考文献：
  名称：

  Potent and selective, sulfamide-based human β3-adrenergic receptor agonists

  摘要：

  A series of sulfamide-based analogs related to L-796568 were prepared and evaluated for their biological activity at the human beta(3)-adrenergic receptor (AR). This modification allows for a significant reduction in molecular weight, while maintaining single-digit nanomolar potencies at the beta(3)-AR and high selectivities versus the beta(1)- or beta(2)-AR. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.089

文献信息

• Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
  申请人：Tang Cho Peng

  公开号：US20050032871A1

  公开（公告）日：2005-02-10

  The present invention relates to compounds having the following chemical structure (Formula I): where the substituents R 1 -R 10 are defined herein. The compounds of this invention are useful in treating disorders related to abnormal kinase activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

  本发明涉及具有以下化学结构（式I）的化合物，其中取代基R1-R10在此定义。本发明的化合物在治疗与异常激酶活性相关的疾病方面具有用途。还公开了包含这些化合物的药物组合物、利用包含这些化合物的药物组合物治疗疾病的方法以及制备它们的方法。
• Beta3 agonists and uses thereof
  申请人：——

  公开号：US20020128247A1

  公开（公告）日：2002-09-12

  Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with &bgr;-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and cardiovascular diseases. 1

  化学式为(I)的磺胺化合物被描述，并且它们在治疗依赖与β-肾上腺素受体相关的信号通路的疾病中的用途也被描述，例如肥胖症、糖尿病、高血压、胃肠道低动力或高动力和心血管疾病。
• US6939867B2
  申请人：——

  公开号：US6939867B2

  公开（公告）日：2005-09-06
• Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
  申请人：Pfizer Products Inc.

  公开号：EP1236723A1

  公开（公告）日：2002-09-04

  Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with β-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and cardiovascular diseases.

  公式（I）的磺胺化合物被描述，并且它们被用于治疗依赖于与β-肾上腺素受体相关的信号通路的疾病，例如肥胖症、糖尿病、高血压、胃肠道低动力或高动力以及心血管疾病。
• Potent and selective, sulfamide-based human β3-adrenergic receptor agonists
  作者：Robert L. Dow、Ernest S. Paight、Steven R. Schneider、John R. Hadcock、Diane M. Hargrove、Kelly A. Martin、Tristan S. Maurer、Nancy A. Nardone、David A. Tess、Paul DaSilva-Jardine

  DOI：10.1016/j.bmcl.2004.03.089

  日期：2004.6

  A series of sulfamide-based analogs related to L-796568 were prepared and evaluated for their biological activity at the human beta(3)-adrenergic receptor (AR). This modification allows for a significant reduction in molecular weight, while maintaining single-digit nanomolar potencies at the beta(3)-AR and high selectivities versus the beta(1)- or beta(2)-AR. (C) 2004 Elsevier Ltd. All rights reserved.